1. Home
  2. TALK vs TBPH Comparison

TALK vs TBPH Comparison

Compare TALK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talkspace Inc.

TALK

Talkspace Inc.

HOLD

Current Price

$3.92

Market Cap

442.1M

Sector

Health Care

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.24

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALK
TBPH
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
442.1M
993.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TALK
TBPH
Price
$3.92
$18.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$4.83
$27.80
AVG Volume (30 Days)
1.2M
490.2K
Earning Date
02-19-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
0.58
Revenue
$214,593,000.00
$80,327,000.00
Revenue This Year
$23.86
$70.78
Revenue Next Year
$22.22
N/A
P/E Ratio
$144.07
$31.74
Revenue Growth
18.37
27.12
52 Week Low
$2.22
$7.90
52 Week High
$4.36
$20.33

Technical Indicators

Market Signals
Indicator
TALK
TBPH
Relative Strength Index (RSI) 68.50 50.55
Support Level $3.45 $17.59
Resistance Level $3.71 $19.22
Average True Range (ATR) 0.16 0.59
MACD 0.01 -0.10
Stochastic Oscillator 99.01 50.38

Price Performance

Historical Comparison
TALK
TBPH

About TALK Talkspace Inc.

Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: